Correction:Journal of Eating Disorders (2023) 11:81 https://doi.org/10.1186/s40337-023-00796-x
The original article [1] has incomplete funding information. The sponsorship from Takeda Pharmaceutical Australia to cover the Article Processing Charge was not mentioned in the Funding note. The correct Funding note is as follows:
Funding
This work was supported by the Nova Scotia Health Authority Research Fund and the Dalhousie Department of Psychiatry (Award No. 1023016). The Nova Scotia Health Authority Research Fund and the Dalhousie Department of Psychiatry were not involved in the design of the study, data collection, analysis and interpretation, or in writing the manuscript. The article has received sponsorship from Takeda Pharmaceutical Australia to cover the Article Processing Charge.
The original article [1] has been corrected.
References
Dixon L, Bartel S, Brown V, et al. Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa. J Eat Disord. 2023;11:81. https://doi.org/10.1186/s40337-023-00796-x.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s40337-023-00796-x.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Dixon, L., Bartel, S., Brown, V. et al. Correction: Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa. J Eat Disord 11, 205 (2023). https://doi.org/10.1186/s40337-023-00926-5
Published:
DOI: https://doi.org/10.1186/s40337-023-00926-5